Top Markets
Coin of the day
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
Rank in Stocks #18278
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Share Price
$1.79
Last synced: 2026-09-02
Market Cap
$205.75M
Change (1 day)
3.18%
Change (1 year)
-61.61%
Country
US
Trade NovaBridge Biosciences (NBP)

Category

Dividend yield history for NovaBridge Biosciences (NBP)
NovaBridge Biosciences (stock symbol: NBP) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for NovaBridge Biosciences (NBP) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors
Company Dividend Yield Country
0.00%
US
0.00%
NL
0.00%
US
2.48%
AU
0.00%
CH